Key takeaways
Glyxambi (empagliflozin / linagliptin) and Ozempic (semaglutide) are both medications used to manage Type 2 diabetes and reduce the risk of heart-related issues in adults with this condition. However, they belong to different medication classes and have distinct mechanisms of action. Glyxambi combines an SGLT2 inhibitor and a DPP-4 inhibitor, working by removing excess sugar through urine and prolonging the action of GLP-1 to increase insulin production. It is taken orally once daily. Ozempic, on the other hand, is a GLP-1 agonist that mimics the natural GLP-1 hormone to lower blood sugar and is available as a weekly injection or daily oral tablet. While Glyxambi is not available in a generic form, Ozempic is also marketed under different brand names for other uses. Common side effects of Glyxambi include urinary tract infections and upper respiratory infections, whereas Ozempic often causes nausea, vomiting, and diarrhea. Both medications can interact with other diabetes treatments, potentially leading to low blood sugar.
